Compounded vs. Brand-Name Semaglutide

Pharmaceutical compounding is the practice of a licensed pharmacist, physician, or outsourcing facility creating a medication tailored to an individual patient. According to the U.S. Food and Drug Administration (FDA), compounding can involve combining, mixing, or altering ingredients — for example, to make a medication without a particular dye for a patient with an allergy, or to prepare a dose or form that is not commercially available.

Compounded drugs serve a recognized role in patient care, but the FDA is explicit on one point: compounded drugs are not FDA-approved. That means the FDA does not verify the safety, effectiveness, or quality of a compounded preparation before it is dispensed to a patient. Brand-name semaglutide products, by contrast, went through the FDA's new-drug approval process before they could be marketed.

Semaglutide is the active ingredient in several FDA-approved products made by Novo Nordisk. The brand-name landscape includes Ozempic and Wegovy (both injectable semaglutide) and Rybelsus (an oral semaglutide tablet). These products have been reviewed by the FDA, are manufactured under federal manufacturing standards, and carry FDA-approved labeling that describes their authorized uses, dosing, and safety information.

Tirzepatide — a different active ingredient sold by Eli Lilly under the brand names Mounjaro and Zepbound — is frequently discussed alongside semaglutide but is a distinct molecule with its own FDA approvals. This guide focuses on semaglutide; the same compounded-vs-brand distinction applies to tirzepatide.

Because these are the FDA-approved versions, they are the products manufacturers support directly. Novo Nordisk operates a manufacturer direct-to-patient self-pay channel (NovoCare Pharmacy), and Eli Lilly offers direct self-pay options through LillyDirect for its tirzepatide products. Pricing on these manufacturer channels is set by the manufacturer and should be verified at the source.

Compounding in the United States is governed primarily by two sections of the Federal Food, Drug, and Cosmetic Act:

• Section 503A covers traditional compounding by state-licensed pharmacies and physicians, generally for an identified individual patient pursuant to a valid prescription.
• Section 503B covers "outsourcing facilities" that register with the FDA and can compound larger batches under federal oversight.

Federal law generally prohibits compounding what is essentially a copy of a commercially available, FDA-approved drug. A key exception exists when a drug is on the FDA's official drug shortage list. Semaglutide and tirzepatide were added to that list in 2022 amid surging demand, which is what enabled widespread compounding of these molecules in the first place.

The shortage-driven era of widespread GLP-1 compounding has wound down. According to the FDA, the tirzepatide shortage was declared resolved in December 2024 and the semaglutide shortage was declared resolved in February 2025. The agency then set time-limited "enforcement discretion" windows giving compounders a period to wind down shortage-based copying — those windows closed during 2025 (the agency announced staggered dates for 503A pharmacies and 503B outsourcing facilities).

This does not mean all compounding stopped. Compounding can continue under the standing rules of sections 503A and 503B — for example, when there is a documented clinical need for an individual patient that an FDA-approved product cannot meet (such as a specific dose or a component a patient cannot tolerate). What changed is that the broad, shortage-based justification for compounding mass copies of these drugs is no longer in effect. Because this is an evolving regulatory area, patients should confirm a provider's current sourcing and the legal basis for any compounded product directly with the provider.

For the FDA's own statements, see the agency's page, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize."

The table below compares the two on neutral, verifiable attributes — regulatory status, who makes them, available formats, and how they are typically priced. It does not compare weight-loss or health outcomes, which depend on the individual and are determined with a licensed provider.

Whether a person ends up with a brand-name or a compounded product, the legal pathway is the same: a consultation with a licensed provider who can write a prescription. There is no legitimate way to obtain prescription semaglutide — brand-name or compounded — without a prescription, and "free samples" of a prescription drug are not something a consumer can request directly outside a clinical setting.

Legitimate ways people reduce cost or access these medications include:

• Telehealth consultations that connect patients with licensed providers, who determine whether a prescription is appropriate.
• Manufacturer savings and direct-to-patient self-pay programs (for example, Novo Nordisk's NovoCare and Eli Lilly's LillyDirect for their respective brands), which publish their own pricing.
• Patient-assistance programs for eligible patients, run by manufacturers or nonprofits.
• Insurance coverage where a plan covers the medication for an approved use.

glp1samples.com maintains an educational directory of telehealth providers that operate in this space. Listings describe real, currently operating providers and their stated formats and starting prices (attributed; verify current pricing at the source). A listing is informational, not an endorsement or medical recommendation.

For adults 18+. Prescription medications require a consultation with a licensed provider. This is not medical advice. Statements not evaluated by the FDA.

This article is educational and does not recommend compounded or brand-name semaglutide, or any specific provider, over another. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before they are dispensed. Regulatory status in this area changes; confirm current FDA guidance at fda.gov and discuss any medication decision with a licensed healthcare provider. Prices and programs referenced are attributed and may change — verify current details directly with the provider or manufacturer.